Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma.
elderly patients
hepatocellular carcinoma
outcome
overall survival
safety
sorafenib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
12
2021
accepted:
28
06
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. Retrospective multicentre study of HCC patients aged ≥75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. The study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS>0 (45.3 vs 34.7%; STD: 38.2) differed significantly between patients receiving low and full doses. Median OS was 15.4 months (18.2 in BCLC-B vs 13.6 in BCLC-C). OS was not modified by comorbidities, age or period with more expertise. Sorafenib appears to be safe in elderly patients with HCC. This is the first study to characterize the profile of elderly patients to be considered for systemic treatment. These findings could be used as the reference profile for elderly candidates for atezolizumab-bevacizumab.
Identifiants
pubmed: 35982971
doi: 10.3389/fonc.2022.829483
pmc: PMC9380437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
829483Informations de copyright
Copyright © 2022 Soria, Calvo, Casas, Vidales, Muñoz-Martínez, Sapena, Puigvehi, Canillas, Guardeño, Gallego, Mínguez, Horta, Clos, Montoliu, Roget, Reig and Vergara.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Hepatol. 2019 Dec;71(6):1175-1183
pubmed: 31449860
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Dig Liver Dis. 2017 Sep;49(9):1043-1049
pubmed: 28712860
Crit Rev Oncol Hematol. 2006 Sep;59(3):243-9
pubmed: 16916608
Clinics (Sao Paulo). 2021 Jan 22;76:e2498
pubmed: 33503195
Liver Cancer. 2019 Nov;8(6):457-467
pubmed: 31799203
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Cancer. 2013 Sep 14;4(8):635-43
pubmed: 24155775
J Gerontol. 1976 Jul;31(4):441-7
pubmed: 774005
Oncologist. 2011;16(3):310-8
pubmed: 21349948
Oncology. 2013;84(5):265-72
pubmed: 23428832
World J Gastroenterol. 2006 Jan 7;12(1):48-53
pubmed: 16440416
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Hepatol Res. 2011 Apr;41(4):296-302
pubmed: 21348907
Br J Cancer. 2021 Jan;124(2):407-413
pubmed: 33071284
Hepatol Res. 2014 Dec;44(13):1329-38
pubmed: 24528772
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Oncologist. 2011;16(12):1721-8
pubmed: 22135121
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55
pubmed: 27623000
Am J Ther. 2007 Sep-Oct;14(5):488-98
pubmed: 17890940
Hepatol Res. 2015 Mar;45(3):279-87
pubmed: 24802232
J Geriatr Oncol. 2020 Sep;11(7):1157-1160
pubmed: 32273248
J Hepatol. 1999 Nov;31(5):860-6
pubmed: 10580583
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Cancer Chemother Pharmacol. 2015 Jan;75(1):215-9
pubmed: 25477009